electroCore to Announce First Quarter Ended March 31, 2020 Financial Results on Thursday, May 14
Rhea-AI Summary
electroCore, Inc. (Nasdaq: ECOR) plans to report its financial results for Q1 2020 on May 14, 2020, after market close. A conference call and webcast will follow at 4:30 PM ET to discuss these results. The company specializes in bioelectronic medicine, focusing on non-invasive vagus nerve stimulation therapies aimed at treating conditions like migraines and cluster headaches. With a commitment to improving patient outcomes, electroCore continues to innovate in the neurology and rheumatology sectors.
Positive
- Focus on innovative non-invasive treatments for headaches.
- Engagement in the bioelectronic medicine market with growth potential.
Negative
- None.
News Market Reaction – ECOR
On the day this news was published, ECOR declined 0.32%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
BASKING RIDGE, N.J., May 07, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced that it will report financial results for the first quarter ended March 31, 2020 after the close of the market on Thursday, May 14, 2020. Management will host a conference call and webcast at 4:30pm Eastern Time to discuss the financial results and answer questions.
| Thursday, May 14 @ 4:30pm Eastern Time | |
| Domestic: | 877-407-4018 |
| International: | 201-689-8471 |
| Conference ID: | 13702250 |
| Webcast: | http://public.viavid.com/index.php?id=139209 |
About electroCore, Inc.
electroCore, Inc. is a commercial-stage bioelectronic medicine company dedicated to improving patient outcomes through its platform non-invasive vagus nerve stimulation therapy initially focused on the treatment of multiple conditions in neurology and rheumatology. The company’s initial targets are the preventative treatment of cluster headache and acute treatment of migraine and episodic cluster headache.
For more information, visit www.electrocore.com.
Investors:
Hans Vitzthum
LifeSci Advisors
617-430-7578
hans@lifesciadvisors.com
or
Media Contact:
Jackie Dorsky
electroCore
973-290-0097
jackie.dorsky@electrocore.com
FAQ
When will electroCore report its Q1 2020 financial results?
What time is the electroCore conference call on May 14, 2020?
What is the focus of electroCore's treatment?
What is the conference ID for the electroCore call?
